Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAGE: Sargramostim Inhalation in Autoimmune PAP
NCT02835742Phase 2Completed
- Sponsor
- Niigata University Medical and Dental Hospital
- Start
- Sep 2016
- Primary completion
- Aug 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of sargramostim in autoimmune pulmonary alveolar proteinosis (aPAP), sponsored by Niigata University Medical and Dental Hospital. Started Sep 2016; status: completed.
02
Drugs
sargramostim
03
Conditions
autoimmune pulmonary alveolar proteinosis (aPAP)
Beyond the preview
Go deeper on NCT02835742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02835742.